{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:01Z","timestamp":1791318901100,"version":"4.3.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.neuropharm.2013.01.023","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T04:46:17Z","timestamp":1360730777000},"page":"211-217","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype"],"prefix":"10.1016","volume":"70","author":[{"given":"Lindsay N.","family":"Cates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Huitron-Resendiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Hedlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.01.023_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in\u00a0vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-6606-4-21","article-title":"Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness","volume":"4","author":"Albert","year":"2011","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib4","doi-asserted-by":"crossref","first-page":"23422","DOI":"10.1016\/S0021-9258(19)49479-9","article-title":"Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase","volume":"268","author":"Bard","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"issue":"Suppl 2","key":"10.1016\/j.neuropharm.2013.01.023_bib5","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1007\/s00406-010-0152-8","article-title":"Is there a personalized medicine for mood disorders?","volume":"260","author":"Bartova","year":"2010","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cne.1109","article-title":"Subcellular distribution of 5-HT1B and 5-HT7 receptors in the mouse suprachiasmatic nucleus","volume":"432","author":"Belenky","year":"2001","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib8","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1021\/jm2000773","article-title":"Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action","volume":"54","author":"Berrade","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1503\/jpn.100098","article-title":"The well of novel antidepressants: running dry","volume":"35","author":"Blier","year":"2010","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.112.193995","article-title":"Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder","volume":"342","author":"Bonaventure","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.107.119404","article-title":"Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents","volume":"321","author":"Bonaventure","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1471-4159.2008.05850.x","article-title":"Antagonism of 5-HT1A receptors uncovers an excitatory effect of SSRIs on 5-HT neuronal activity, an action probably mediated by 5-HT7 receptors","volume":"108","author":"Bosker","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3810\/pgm.2011.03.2273","article-title":"Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics","volume":"123","author":"Citrome","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/mp.2008.13","article-title":"Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication","volume":"14","author":"Druss","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-007-1035-1","article-title":"Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment","volume":"199","author":"Elizalde","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/026988119701100409","article-title":"Effects of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice","volume":"11","author":"Ferrari","year":"1997","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","article-title":"Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress","volume":"15","author":"Fumagalli","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.4088\/JCP.v64n1211","article-title":"The economic burden of depression in the United States: how did it change between 1990 and 2000?","volume":"64","author":"Greenberg","year":"2003","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2004.11.015","article-title":"Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression","volume":"48","author":"Guscott","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1023\/B:NERE.0000029560.14262.39","article-title":"A\u00a05-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction","volume":"29","author":"Harsing","year":"2004","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: an overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1073\/pnas.0337340100","article-title":"No hypothermic response to serotonin in 5-HT7 receptor knockout mice","volume":"100","author":"Hedlund","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biopsych.2005.05.012","article-title":"5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern","volume":"58","author":"Hedlund","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-HT7 receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1254\/jphs.08201SC","article-title":"Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test","volume":"108","author":"Kamei","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00023210-200923020-00002","article-title":"Current considerations in the treatment of generalized anxiety disorder","volume":"23","author":"Katzman","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1517\/14728210903107751","article-title":"Emerging drugs for major depressive disorder","volume":"14","author":"Kennedy","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0327(96)00103-6","article-title":"Amisulpride versus imipramine and placebo in dysthymia and major depression","volume":"43","author":"Lecrubier","year":"1997","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0896-6273(93)90149-L","article-title":"A\u00a0novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms","volume":"11","author":"Lovenberg","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib37","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/en.2008-1721","article-title":"Influence of sex and corticotropin-releasing factor pathways as determinants in serotonin sensitivity","volume":"150","author":"McEuen","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib41","first-page":"581","article-title":"S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine","volume":"298","author":"Millan","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/npp.2011.13","article-title":"Pharmacological blockade of 5-HT(7) receptors as a putative fast acting antidepressant strategy","volume":"36","author":"Mnie-Filali","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2174\/138945009789735129","article-title":"Therapeutic potential of 5-HT(7) receptors in mood disorders","volume":"10","author":"Mnie-Filali","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145709990630","article-title":"Differential effects of acute and repeated citalopram in mouse models of anxiety and depression","volume":"13","author":"Mombereau","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1440-1681.2007.04608.x","article-title":"5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression","volume":"34","author":"Nandam","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib47","first-page":"937","article-title":"Augmentation treatment in major depressive disorder: focus on aripiprazole","volume":"4","author":"Nelson","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib48","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/026988110001400106","article-title":"Antidepressant-like activity of amisulpride in two animal models of depression","volume":"14","author":"Papp","year":"2000","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib50","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuron.2009.12.003","article-title":"5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants","volume":"65","author":"Richardson-Jones","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib52","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1073\/pnas.90.18.8547","article-title":"Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation","volume":"90","author":"Ruat","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"Sanchez","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2010.01.022","article-title":"The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior","volume":"209","author":"Sarkisyan","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib55","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib56","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1016\/S0021-9258(17)46830-X","article-title":"Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype","volume":"268","author":"Shen","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-0327(97)00139-0","article-title":"Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study","volume":"48","author":"Smeraldi","year":"1998","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib59","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0149-2918(97)80066-5","article-title":"Fluoxetine tenth anniversary update: the progress continues","volume":"19","author":"Stokes","year":"1997","journal-title":"Clin. Ther."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib60","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.pnpbp.2007.04.010","article-title":"Reduced evoked fos expression in activity-related brain regions in animal models of behavioral depression","volume":"31","author":"Stone","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0936s54","article-title":"Open-space forced swim model of depression for mice","author":"Stone","year":"2011","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pbb.2008.07.006","article-title":"Evaluation of the repeated open-space swim model of depression in the mouse","volume":"91","author":"Stone","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib63","first-page":"464","article-title":"Influence of serotonin 5-HT7 receptor blockade on the behavioral and neurochemical effects of imipramine in rats","volume":"60","author":"Wesolowska","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejphar.2006.09.064","article-title":"Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats","volume":"553","author":"Wesolowska","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.01.023_bib65","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuropharm.2006.04.017","article-title":"Effect of the selective 5-HT(7) receptor antagonist SB 269970 in animal models of anxiety and depression","volume":"51","author":"Wesolowska","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.01.023_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2006.10.001","article-title":"Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice","volume":"555","author":"Wesolowska","year":"2007","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813000403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813000403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T10:57:03Z","timestamp":1617620223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813000403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":66,"alternative-id":["S0028390813000403"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.01.023","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}